Acute Lymphoblastic Leukemia
Conditions
Keywords
Leukemia
Brief summary
The primary objective of this study (TOTXVI) is to compare the clinical benefit, the pharmacokinetics, and the pharmacodynamics of polyethylene glycol-conjugated (PEG) asparaginase given in higher dose (HD PEG) versus those of PEG-asparaginase given in conventional dose (CD PEG) during the continuation phase. This study has several secondary objectives: Therapeutic Objectives: To estimate the event-free survival and overall survival of children with ALL who are treated with risk-directed therapy. To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD \> 5%, will result in improved leukemia cytoreduction in this subgroup compared to TOTXV. To assess whether intensification of central nervous system (CNS)-directed intrathecal and systemic chemotherapy will improve outcome in patients at high risk of CNS relapse. Exploratory Pharmacologic Objectives: To identify pharmacogenetic, pharmacokinetic and pharmacodynamic predictors for treatment-related outcomes in the context of the systemic therapy used in the protocol. To compare the pharmacokinetics and pharmacodynamics of PEG-asparaginase given in higher dose (3,500 or 3,000 units/m2) versus those of PEG-asparaginase given in conventional dose (2,500 units/m2) in the continuation phase. Exploratory Biologic Objectives: To determine the prognostic value of levels of minimal residual disease in peripheral blood at day 8 of remission induction. To validate new markers and methods for MRD detection. To genotype natural killer (NK) cell receptors and measure their expressions at diagnosis and before reinduction, and to associate these features with treatment outcome. To identify new prognostic factors by applying new technologies to study patient material (e.g., stored plasma, serum, cerebrospinal fluid, and normal and leukemic cells). Exploratory Neuroimaging Objectives: To use quantitative MR measures (Diffusion Tensor Imaging and high resolution volumetric imaging) to assess differences in myelin and cortical thickness development in patients treated for ALL relative to healthy controls matched for age and gender. To assess the impact of folate pathway genetic polymorphisms on myelin and cortical thickness development and neurocognitive performance. To assess the impact of frontal-parietal lobe myelin and cortical thickness development on neurocognitive performance in attention, working memory, fluency, visual-spatial reasoning and processing speed.
Detailed description
Details of the Treatment Plan: Treatment will consist of three main phases: Remission Induction, Consolidation, and Continuation. 1. Remission Induction * Intrathecal Treatment during Induction Frequency and total number of triple intrathecal treatments for Remission Induction is based on the patient's risk of CNS relapse.All patients will receive triple intrathecal treatment on days 1 and 15. Patients with high risk features may receive additional triple intrathecal treatment on days 4, 8, 11, and 22.\[t(1;19)/E2A-PBX1. Induction treatment will begin with prednisone, vincristine, daunorubicin, PEG-asparaginase and triple intrathecal treatment, followed by cyclophosphamide plus cytarabine plus thioguanine. Remission Induction Chemotherapy (6-7 weeks) Prednisone 40 mg/m2/day PO (divided t.i.d.) Days 1 - 28 Dexamethasone will be substituted for prednisone in patients with early T-cell precursor (ETP) immunophenotype. Mercaptopurine will be substituted for thiopurine in TPMT HET/deficient patients Dexamethasone (for ETP immunophenotype only) 10 mg/m2/day PO (divided t.i.d.)Days 1-21; 4 mg/m2/day PO (divided t.i.d) Days 22-24; 2 mg/m2/day PO(divided t.i.d) Days 25-28 Vincristine 1.5 mg/m2 IV (max 2 mg) Days 1, 8, 15, 22 Daunorubicin 25 mg/m2 IV Days 1 and 8 PEG-asparaginase 3,000 Units/m2 IV Day 3 \- Participants with Day 15 MRD greater than or equal to 1%: PEG-asparaginase 3,000 Units/m2 IV Day 15 \- Participants with Day 15 MRD less than 5% (excluding MLL positive infants): Cyclophosphamide 1000 mg/m2 IV Day 22 Cytarabine 75 mg/m2/dose IV Days 23-26, 30-33 Thioguanine \[Mercaptopurine (TPMT HET/deficient patients only)\]60 mg/m2/dose PO Days 22-35 Dasatinib (Ph+ participants only) 40 mg/m2 b.i.d starting Day 22 of induction to continue until end of treatment Day 15 MRD \> or equal to 5% (excluding MLL+ infants) Cyclophosphamide† 300 mg/m2 IV/ q12 hrs on Days 22-23 Cytarabine 75 mg/m2/dose IV Days 23-26, 30-33 Thioguanine \[Mercaptopurine (TPMT HET/deficient patients only) 60 mg/m2/dose PO Days 22-35 Dasatinib‡ (Ph+ participants only) 40 mg/m2 b.i.d Daily Starting Day 22 of induction to continue until end of treatment \- Infants with MLL positive rearrangement: Clofarabine 40 mg/m2/dose IV Days 22-26 Etoposide 100 mg/m2/dose IV Days 22-26 Cyclophosphamide 300 mg/m2/dose IV Days 22-26 2. Consolidation Treatment (8 weeks) High Dose Methotrexate (HDMTX) 2.5 gm/ (low risk), or targeted 65 μM (std/high-risk) days 1, 15, 29 and 43. Mercaptopurine 50 mg/m2/day Days 1 to 56. All patients will receive triple intrathecal therapy every other week for four doses on Days 1, 15, 29, and 43. Dose is age dependent. \- Reintensification Patients with high-risk leukemia may receive reintensification therapy and then will be offered the option of transplant. This treatment will attempt to maximize leukemic cell kill before allogeneic hematopoietic stem cell transplantation. Dexamethasone 20 mg/m2/day PO or IV Days 1-6.Cytarabine 2 grams/m2, 3-hour IV infusion every 12 hours Days 1-2. Etoposide 100 mg/m2, 1-hour IV infusion every 12 hours Days 3-5. Intrathecal methotrexate+hydrocortisone+cytarabine (ITMHA) Day 5; PEG-asparaginase 3,000 units/m2 IV Day 6 Patients with suboptimal response to reintensification may receive one to two cycles of clofarabine/cyclophosphamide/etoposide/dexamethasone: Clofarabine 40 mg/m2/day, 2-hour IV infusion Days 1-5 Etoposide 100 mg/m2/day, 2-hour IV infusion Days 1-5 Cyclophosphamide 300 mg/m2/day, 30-60 minute IV infusion Days 1-5 Dexamethasone 8 mg/m2/day (divided t.i.d) Days 1-5 3. Continuation Treatment (120 weeks) Abbreviations used below: DEX=dexamethasone; DOX=doxorubicin; VCR=vincristine; MP=mercaptopurine; PEG-ASP=polyethylene glycol-conjugated asparaginase; MTX=methotrexate; 6MP=mercaptopurine Weeks 1 through 20 - treatment depends on risk assignment standard-high versus low-risk Week Standard-/High-Risk Low-Risk 1. DEX+DOX+VCR+MP + PEG-ASP/MP + DEX + VCR 2. MP MP + MTX 3. MP + PEG-ASP/MP + MTX 4. DEX + DOX + VCR + MP/MP + DEX + VCR 5. MP + PEG-ASP MP + MTX 6. MP MP + MTX 7. Reinduction I 8. Reinduction I 9. Reinduction I 10. MP/MP + MTX 11. DOX + VCR +MP + PEG-ASP/MP + MTX 12. MP/MP + MTX 13. MP + PEG-ASP/MP + MTX 14. DEX + DOX + VCR +6MP/MP + DEX + VCR 15. MP + PEG-ASP/MP + MTX 16. MP/MP + MTX 17. Reinduction II 18. Reinduction II 19. Reinduction II 20. No chemotherapy/MP + MTX Drug Dosages, Schedules and Routes for Continuation Therapy Weeks 1 to 6 and 10 to 16: Dexamethasone 12 mg/m2 (std/high risk) or 8 mg/m2 (low risk) PO daily (divided t.i.d.) for 5 days, Days 1-5. Doxorubicin 30 mg/m2 IV, Day 1. Vincristine 2 mg/m2 IV push (max. 2 mg), Day 1 (0.05 mg/kg for patients \< 1 year of age or \< 10kg in weight). MP (mercaptopurine) 50 mg/m2 PO daily for 7 days (std/high risk), Days 1-7, 75 mg/m2 PO daily for 7 days (low risk), Days 1-7. PEG-ASP (PEG-asparaginase) 2,500 vs. 3,500 units/m2 IV randomization, Day 1. Methotrexate 40 mg/m2 IV Day 1. Dexamethasone, vincristine, and asparaginase will be given regardless of blood counts, provided that the patient is clinically well. Doxorubicin, mercaptopurine and methotrexate will be held if white blood count (WBC) \<1000/mm3 or absolute neutrophil count (ANC) \<300/mm3. Doxorubicin, mercaptopurine and methotrexate will be reduced for WBC \< 1500/mm3, or if WBC and ANC not increase by at least 2 folds a week after the start date of dexamethasone pulse. Reinduction Treatment - This phase of treatment is part of continuation and will be started at weeks 7 and 17 after bone marrow examination confirms complete remission. Doxorubicin and HD-cytarabine will be held if ANC \< or equal to 300/mm3 or WBC \< 1000/mm3.It is preferable to start HD-cytarabine when WBC \> or equal to 1800/mm3 and ANC \> 300/mm3 Reinduction treatment will be given twice: weeks 7 to 9 and weeks 17 to 19 for all patients. Intrathecal treatment will be followed by leucovorin rescue (5 mg/m2/dose PO, max 5 mg) at 24 and 30 hours only in patients with prior CNS toxicities or in patients with WBC \< 1500/mm3, or ANC \< 500/mm3. \- Reinduction I for Standard/High Risk ALL excluding MLL infants: Dexamethasone 8 mg/m2/day PO (divided t.i.d.) Days 1-8, 15-21. Vincristine 1.5 mg/m2/week IV Days 1, 8, 15 Doxorubicin 30 mg/m2 IV Days 1, 8. PEG-asparaginase 2,500 or 3,500 units/m2 IV Days 1, 15. Intrathecal chemotherapy, Methotrexate + hydrocortisone + Ara-C dose age dependent, Day 1. \- Reinduction II for Standard/High Risk ALL including MLL infants: Dexamethasone 8 mg/m2/day PO (t.i.d.) Days 1-8, 15-21. Vincristine 1.5 mg/m2/week IV Days 1, 8, 15. PEG-asparaginase 2,500 or 3,500 units/m2 IV Days 1, 15. High-dose cytarabine 2 gm/m2 IV q 12 hr Days 15, 16. Intrathecal chemotherapy, dose age dependent, Day 1. \- Reinduction I for Low-Risk ALL: Dexamethasone 8 mg/m2/day PO (divided t.i.d.) Days 1-8, 15-21. Vincristine 1.5 mg/m2/week IV Days 1, 8, 15. PEG-asparaginase 2,500 or 3,500 units/m2 IV Days 1, 15. Doxorubicin 30 mg/m2/IV Day 1. Intrathecal chemotherapy, dose age dependent, Day 1. \- Reinduction II for Low-Risk ALL: Dexamethasone 8 mg/m2/day PO (divided t.i.d.) Days 1-8, 15-21. Vincristine 1.5 mg/m2/week IV Days 1, 8, 15. PEG-asparaginase 2,500 or 3,500 units/m2 IV Days 1, 15. Intrathecal chemotherapy, dose age dependent, Day 1. \- Reinduction I for MLL Infants: Dexamethasone 8 mg/m2/day PO (divided t.i.d.) Days 1-8 and 15-21. Clofarabine 40 mg/m2/day, -hour IV Days 1-5. Etoposide 100 mg/m2/day, 2-hour IV Days 1-5. cyclophosphamide 300 mg/m2/day, 1-hour IV Days 1-5. PEG-asparaginase 2,500 or 3,500 units/m2 IV Days 1, 15. Intrathecal chemotherapy, dose age dependent, on Day 1. \- Intrathecal Chemotherapy: * Triple intrathecal treatment will be given to low-risk cases with CNS-1 status (no identifiable blasts in CSF) on weeks 7, 12, 17, 25, 33, 41, and 49. * Triple intrathecal treatment will be given to low-risk cases with CNS-2, traumatic CSF with blasts status, or WBC \> 100 x 109/L on weeks 3, 7, 12, 17, 25, 29, 33, 37, 41, 45 and 49. * Triple intrathecal treatment will be given to standard/high-risk cases on weeks 7, 12, 17, 25, 29, 33, 37, 41, 45 and 49. * Triple intrathecal treatment will be given to other standard/high-risk cases with WBC \> or equal to 100 x 109/L, T-cell ALL, t (1;19)/E2A-PBX1, presence of Philadelphia chromosome, MLL rearrangement, hypodiploidy \<44, CNS-2 or CNS-3 status, or traumatic lumbar puncture with blasts on weeks 3, 7, 12, 17, 25, 29, 33, 37, 41, 45, 49, 57, 65, 73, 81, 89 and 97 Treatment (weeks 21 to 29) Week Standard/High Risk Low Risk 21. MP + PEG-ASP+Dasatinib MP + MTX 22. MP +Dasatinib MP + MTX 23. MP + PEG-ASP + Dasatinib MP + MTX 24. Cyclo + Ara-C + Dasatinib MP + MTX 25. DEX + VCR + PEG-ASP + Dasatinib MP + DEX + VCR 26. MP + Dasatinib MP + MTX 27. MP + PEG-ASP+Dasatinib MP + MTX 28. Cyclo + Ara-C + Dasatinib MP + MTX 29. DEX + VCR +PEG-ASP + Dasatinib MP + DEX + VCR Dasatinib in Ph+ only Treatment (weeks 30 to end of therapy) Week Standard/High Risk Low Risk 30. MP + MTX + Dasatinib MP + MTX 31. MP + MTX + Dasatinib MP + MTX 32. Cyclo + Ara-C+Dasatinib MP + MTX 33. DEX + VCR + Dasatinib MP + DEX + VCR 34. MP + MTX + Dasatinib MP + MTX 35. MP + MTX + Dasatinib MP + MTX 36. Cyclo + Ara-C + Dasatinib/MP + MTX 37. DEX + VCR + Dasatinib /MP + DEX + VCR Dasatinib in Ph positive patients only Drug Dosages, Schedules and Routes for Continuation Therapy from Week 21 to End of Therapy: Mercaptopurine 75 mg/m2 PO daily for 7 days, Days 1-7. Methotrexate 40 mg/m2 IV or intramuscularly (IM) Day 1. Cyclophosphamide 300 mg/m2 IV, Day 1. Cytarabine 300 mg/m2 IV, Day 1. Dexamethasone 12 mg/m2 (std/high risk) or 8 mg/m2 (low risk) PO daily (divided t.i.d.) for 5 days, Day 1-5 (between week 21 and week 68).Decrease dexamethasone to 6 mg/m2 PO daily (divided t.i.d.) x 5 days,Day 1-5 between week 69 and week 101 for all risk groups. Vincristine2 mg/m2 IV push (max 2 mg), Day 1 (0.05mg/kg for patients \< 1 year or \< 10 kg). PEG-ASP 2,500 vs 3,500 units/m2 IV randomization (until week 30) Dexamethasone, vincristine, and asparaginase will be given regardless of blood counts, provided that the patient is clinically well. Cyclophosphamide, cytarabine, mercaptopurine and methotrexate will be held if WBC \<1000/mm3 or ANC \<300/mm3. Mercaptopurine and methotrexate will be reduced for WBC \< 1500/mm3, or if WBC and ANC do not increase by at least 2 folds a week after the start date of dexamethasone pulse. Doses of cyclophosphamide and cytarabine may need to be reduced if patient misses 25% of chemotherapy and if the low counts deem to be related to this combination. The same treatment (weeks 30-37) will be repeated for a total of 5 times, until week 69 (see Section 5.5.3 for intrathecal therapy). After week 69, all patients will receive daily mercaptopurine and weekly methotrexate interrupted with pulses of dexamethasone, vincristine, and mercaptopurine every 4 weeks. The dose of dexamethasone will be decreased to 6 mg/m2 between week 69 and week 101, after which only mercaptopurine and methotrexate will be given. Intrathecal treatment will be given every 8 weeks only to patients at risk of CNS relapse after week 49 and will be discontinued after week 97. Continuation therapy will be discontinued after 120 weeks. Hematopoietic Stem Cell Transplantation (for patients who meet the criteria of high-risk ALL are candidates for allogeneic hematopoietic stem cell transplantation). However, if the option is declined by the patients or guardians, or the procedure is deemed unsuitable by the attending physician and the principal investigator, the patient will remain on study and continue to receive chemotherapy.
Interventions
DRUGPrednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
See Detailed Description section for details of treatment interventions.
DRUGClofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
See Detailed Description section for details of treatment interventions.
Sponsors
National Cancer Institute (NCI)
Enzon Pharmaceuticals, Inc.
National Institute of General Medical Sciences (NIGMS)
St. Jude Children's Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Participant has a confirmed diagnosis of precursor B-cell or precursor T-cell acute lymphocytic leukemia (ALL) by immunophenotyping * Participant is less than or equal to 18 years of age * Limited prior therapy, including systemic glucocorticoids for one week or less, one dose of vincristine, emergency radiation therapy to the mediastinum and one dose of intrathecal chemotherapy. Other circumstances must be cleared by principal investigator (PI) or co-PI. * Written, informed consent and assent following Institutional Review Board, NCI, FDA, and Office for Human Research Protections (OHRP) Guidelines.
Exclusion criteria
* Participants with prior therapy, other than that listed above * Pregnant or lactating * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. | 3.5 years after the last enrollment up to 12.5 years | The primary objective of this study is to compare the distributions of continuous complete remission of patients randomized on the first day of the continuation phase to receive a higher dose of PEG-asparaginase or to receive the conventional dose (2,500 units/m2). The randomization will occur on the starting day of the continuation phase, at which time all information necessary for performing the randomization should be available. In the rare case that immunophenotype and/or Day-15 MRD is not available, we will make the following assumptions: If immunophenotype is unknown at the time the randomization is to be executed, then it will be assumed B-lineage. If Day-15 MRD is unknown at the time of randomization, then it will be assumed negative (\<0.01%). Past experience indicate that few patients will fall into these unknown categories. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Probability of Event-free Survival | For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years | To estimate the event-free survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV (NCT00137111). EFS will be measured from the date of complete response to the date of initial failure for patients who fail. Failure includes the traditional endpoints of failure to achieve a complete remission, relapse in any site, secondary malignancy, and death during induction or remission. EFS time will be measured to the date of last contact for patients who are failure free at the time of analysis. The EFS time is defined to be zero (0) for patients who die during induction therapy or fail to achieve a complete remission. |
| Probability of Overall Survival | For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years | To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV. |
| Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5% | Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV | To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. |
| Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01% | End of remission induction; day 42 in Total XVI and day 46 in Total XV | To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. |
| Probability of CNS Relapse | For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years | To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse. |
Countries
United States
Participant flow
Recruitment details
Between October 29, 2007 and March 26, 2017, 600 patients younger than 19 years of age with newly diagnosed Acute Lymphoblastic Leukemia (ALL) were enrolled.
Pre-assignment details
Two (2) were later found ineligible and excluded. Of the 598 eligible patients, 414 patients were randomized to the two treatment arms, 184 were not randomized for various reasons: * Not Eligible for Randomization (n=41) * Death (n=5) * Transplant (n=13) * Withdrawal of Consent (n=3) * Down's Syndrome (n=12) * Poor Organ Function (n=8) * Parent/Patient Decision (n=70) * Attending Physician Decision (n=4) * Enrollment after Completion of Randomization (n=69)
Participants by arm
| Arm | Count |
|---|---|
| PEG 3500 Units/m^2 Patients randomized on the first day of continuation phase to receive 3500 units/m\^2 dose of PEG-asparaginase | 206 |
| PEG 2500 Units/m^2 Patients randomized on the first day of continuation phase to receive 2,500 units/m\^2 dose of PEG-asparaginase | 208 |
| Not Randomized Patients who came off study prior to randomization | 184 |
| Total | 598 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Bone Marrow (BM) or Extramedullary Relapse | 3 | 4 | 4 |
| Overall Study | Death | 1 | 4 | 13 |
| Overall Study | Failure to achieve Complete Remission (CR) | 1 | 0 | 1 |
| Overall Study | Participant/Family Withdraw | 2 | 3 | 5 |
| Overall Study | Physician Decision | 0 | 0 | 4 |
| Overall Study | Second Malignancy | 1 | 0 | 0 |
| Overall Study | Transplant | 3 | 3 | 18 |
| Overall Study | Unacceptable Toxicity | 1 | 6 | 6 |
Baseline characteristics
| Characteristic | PEG 2500 Units/m^2 | Not Randomized | PEG 3500 Units/m^2 | Total |
|---|---|---|---|---|
| Age, Continuous | 7.04 years STANDARD_DEVIATION 4.73 | 7.75 years STANDARD_DEVIATION 5.04 | 7.13 years STANDARD_DEVIATION 4.78 | 7.29 years STANDARD_DEVIATION 4.85 |
| Age, Customized >10 years | 45 Participants | 49 Participants | 49 Participants | 143 Participants |
| Age, Customized 1-10 years | 160 Participants | 131 Participants | 152 Participants | 443 Participants |
| Age, Customized <1 year | 3 Participants | 4 Participants | 5 Participants | 12 Participants |
| Race/Ethnicity, Customized Black | 29 Participants | 25 Participants | 34 Participants | 88 Participants |
| Race/Ethnicity, Customized Cuban | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Mexican/Chicano | 5 Participants | 7 Participants | 7 Participants | 19 Participants |
| Race/Ethnicity, Customized Non Spanish speaking, Non Hispanic | 187 Participants | 161 Participants | 182 Participants | 530 Participants |
| Race/Ethnicity, Customized NOS Spanish,Hispanic,Latino | 14 Participants | 13 Participants | 13 Participants | 40 Participants |
| Race/Ethnicity, Customized Other | 12 Participants | 16 Participants | 18 Participants | 46 Participants |
| Race/Ethnicity, Customized Puerto Rican | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized South or Central Amercian | 0 Participants | 2 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Unknown | 2 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 167 Participants | 143 Participants | 154 Participants | 464 Participants |
| Region of Enrollment United States | 208 participants | 184 participants | 206 participants | 598 participants |
| Sex: Female, Male Female | 85 Participants | 72 Participants | 91 Participants | 248 Participants |
| Sex: Female, Male Male | 123 Participants | 112 Participants | 115 Participants | 350 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 9 / 206 | 15 / 208 | 22 / 184 |
| other Total, other adverse events | 206 / 206 | 208 / 208 | 184 / 184 |
| serious Total, serious adverse events | 0 / 206 | 0 / 208 | 2 / 184 |
Outcome results
Primary
Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
The primary objective of this study is to compare the distributions of continuous complete remission of patients randomized on the first day of the continuation phase to receive a higher dose of PEG-asparaginase or to receive the conventional dose (2,500 units/m2). The randomization will occur on the starting day of the continuation phase, at which time all information necessary for performing the randomization should be available. In the rare case that immunophenotype and/or Day-15 MRD is not available, we will make the following assumptions: If immunophenotype is unknown at the time the randomization is to be executed, then it will be assumed B-lineage. If Day-15 MRD is unknown at the time of randomization, then it will be assumed negative (\<0.01%). Past experience indicate that few patients will fall into these unknown categories.
Time frame: 3.5 years after the last enrollment up to 12.5 years
Population: Per protocol, the comparison was between the two randomization arms.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PEG 3500 Units/m^2 | Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. | 91.6 Percentage of participants |
| PEG 2500 Units/m^2 | Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. | 90.7 Percentage of participants |
p-value: 0.778Cochran-Mantel-Haenszel
Secondary
Probability of CNS Relapse
To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse.
Time frame: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years
Population: Patients with features associated with increased risk for CNS relapse in Total XVI and Total XV.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PEG 3500 Units/m^2 | Probability of CNS Relapse | 0.8 Percentage of participants |
| PEG 2500 Units/m^2 | Probability of CNS Relapse | 1.8 Percentage of participants |
| TOTXVI Not Randomized | Probability of CNS Relapse | 2.7 Percentage of participants |
| All Eligible Patients in TOTXV | Probability of CNS Relapse | 5.7 Percentage of participants |
Secondary
Probability of Event-free Survival
To estimate the event-free survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV (NCT00137111). EFS will be measured from the date of complete response to the date of initial failure for patients who fail. Failure includes the traditional endpoints of failure to achieve a complete remission, relapse in any site, secondary malignancy, and death during induction or remission. EFS time will be measured to the date of last contact for patients who are failure free at the time of analysis. The EFS time is defined to be zero (0) for patients who die during induction therapy or fail to achieve a complete remission.
Time frame: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years
Population: Per protocol this objective is to study whether intensifying induction will result in improved outcome compared to TOTXV. All eligible patients entered on TOTXVI will be included in these analyses, as appropriate. Infants will be excluded from the Total XVI for comparisons with TOTXV as only children at least one year of age at diagnosis were treated on Total XV.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PEG 3500 Units/m^2 | Probability of Event-free Survival | 92.4 Percentage of participants |
| PEG 2500 Units/m^2 | Probability of Event-free Survival | 91.1 Percentage of participants |
| TOTXVI Not Randomized | Probability of Event-free Survival | 86.3 Percentage of participants |
| All Eligible Patients in TOTXV | Probability of Event-free Survival | 87.1 Percentage of participants |
Secondary
Probability of Overall Survival
To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV.
Time frame: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years
Population: All eligible patients entered on TOTXVI will be included in these analyses, as appropriate. Infants will be excluded from the Total XVI for comparisons with TOTXV as only children at least one year of age at diagnosis were treated on Total XV.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PEG 3500 Units/m^2 | Probability of Overall Survival | 97.5 Percentage of participants |
| PEG 2500 Units/m^2 | Probability of Overall Survival | 95.6 Percentage of participants |
| TOTXVI Not Randomized | Probability of Overall Survival | 90.8 Percentage of participants |
| All Eligible Patients in TOTXV | Probability of Overall Survival | 93.5 Percentage of participants |
Secondary
Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol.
Time frame: End of remission induction; day 42 in Total XVI and day 46 in Total XV
Population: We will compare the proportion of patients with Day-15 MRD≥5% on TOTXVI who are Day-42 MRD positive with the proportion of Day-46 MRD positives in the corresponding subgroup in TOTXV by Fisher's exact test.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PEG 3500 Units/m^2 | Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01% | 7 Participants |
| PEG 2500 Units/m^2 | Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01% | 12 Participants |
| TOTXVI Not Randomized | Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01% | 20 Participants |
| All Eligible Patients in TOTXV | Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01% | 44 Participants |
Secondary
Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol.
Time frame: Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV
Population: The analysis will compare the proportion of TOTXV patients who had Day-19 MRD≥5% with the proportion of patients on TOTXVI with Day-15 MRD≥5%.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PEG 3500 Units/m^2 | Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5% | 22 Participants |
| PEG 2500 Units/m^2 | Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5% | 26 Participants |
| TOTXVI Not Randomized | Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5% | 31 Participants |
| All Eligible Patients in TOTXV | Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5% | 55 Participants |